Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Esperion Therapeutics Inc.

www.esperion.com

Latest From Esperion Therapeutics Inc.

Finance Watch: Gene Therapy, Targeted Oncology Driving IPOs Despite Biopharma Stock Shakiness

Public Company Edition: Jefferies report notes robust IPO market, but SVB Leerink predicts a financing slowdown. Also, Mirati raises cash for KRAS programs after Amgen's ASCO data and a strategic shift results in job cuts at ImmunoGen.

Financing Deals

Keeping Track Of Non-Oncology Review and Approval News: Erectile Dysfunction, Parkinson's, Cholesterol

The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation

Asia Deal Watch: Boost For Esperion's Cholesterol Candidate As Daiichi Brought On Board

Daiichi Sankyo pays $150m upfront to commercialize Esperion's cholesterol drug and combination in Europe, while Gilead enters major deal worth up to $785m with Korea's Yuhan to bolster its NASH portfolio. Samsung taps 3SBio to build its biosimilars business in China. 
Deals Asia Pacific

What The New US Cholesterol Treatment Guidelines Mean For Esperion

Guidelines place high emphasis on low cost, but also outcomes data. Esperion plans to file bempedioc acid next year, but outcomes data won’t be available until 2022.

Cardiovascular Cost Effectiveness
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Esperion Therapeutics Inc.
  • Pfizer Inc.
  • Senior Management
  • Timothy Mayleben, Pres. & CEO
    Rick Bartram, CFO
    Narendra Lalwani, PhD, EVP, R&D
    Mark Glickman, Chief Commercial Officer
  • Contact Info
  • Esperion Therapeutics Inc.
    Phone: (734) 862-4840
    3891 Ranchero Dr., Ste. 150
    Ann Arbor, MI 48108
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register